Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals's GHG Emissions Data Preview
In 2023, Regeneron Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Regeneron Pharmaceuticals has also provided a category-level breakdown for 6 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Regeneron Pharmaceuticals's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Regeneron Pharmaceuticals amounted to 122,700 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Regeneron Pharmaceuticals increased by 9.36%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Regeneron Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Regeneron Pharmaceuticals's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Regeneron Pharmaceuticals were 69,600 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Regeneron Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2018, Regeneron Pharmaceuticals's Scope 1 emissions have increased by 19.59%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Regeneron Pharmaceuticals's Scope 1 emissions increased by 5.78%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Regeneron Pharmaceuticals's Scope 2 emissions?
In 2023, Regeneron Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 29,900 tCOâ‚‚e using the market-based method, and 53,100 tCOâ‚‚e using the location-based method.
Has Regeneron Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2018, Regeneron Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 28.26%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Regeneron Pharmaceuticals's Scope 2 emissions (Location-Based) rose by 14.44% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
What methodology does Regeneron Pharmaceuticals use for Scope 2 reporting?
In 2023, Regeneron Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.
Regeneron Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Regeneron Pharmaceuticals's Value Chain Emissions
In 2023, Regeneron Pharmaceuticals reported 872,876 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Regeneron Pharmaceuticals includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Regeneron Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Regeneron Pharmaceuticals's Scope 3 emissions?
In 2023, Regeneron Pharmaceuticals reported total Scope 3 emissions of 872,876 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
Has Regeneron Pharmaceuticals reduced its Scope 3 emissions over time?
Since 2018, Regeneron Pharmaceuticals's Scope 3 emissions have increased by 121.22%, reflecting a rising long-term trend in Scope 3 emissions over time.
Compared to the previous year (2022), Regeneron Pharmaceuticals's Scope 3 emissions increased by 26.64%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Regeneron Pharmaceuticals disclose?
In 2023, Regeneron Pharmaceuticals reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol.
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Regeneron Pharmaceuticals's Scope 3 emissions?
In 2023, the largest contributors to Regeneron Pharmaceuticals's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 660,589 tCOâ‚‚e (75.68%)
- Capital Goods (Cat. 2): 115,843 tCOâ‚‚e (13.27%)
- Fuel- and Energy-Related Services (Cat. 3): 39,335 tCOâ‚‚e (4.51%)
Regeneron Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Regeneron Pharmaceuticals's Total Carbon Footprint
In 2023, Regeneron Pharmaceuticals reported a total carbon footprint of 995,576 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 24.22% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Regeneron Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 87.68% of the company's total carbon footprint, followed by Scope 1 emissions at 6.99%.